Anticancer drug | Condition | IC50 in examined cell lines [nmol] | ||||
---|---|---|---|---|---|---|
CMT-U27 | CMT-U309 | P114 | CMT-W1 | CMT-W2 | ||
vinblastine | ctrl | 1 588 | 2 472 | 2 744 | 8 072 | 9 434 |
pgp siRNA | 203*** | 464*** | 208*** | 1 391*** | 1 264*** | |
bcrp siRNA | 1 497 | 2 417 | 2 572 | 8 002 | 7 346 | |
mrp1 siRNA | 144*** | 772** | 756** | 1 747*** | 1 248*** | |
mrp3 siRNA | 1 330 | 2 406 | 2 561 | 7 433 | 8 482 | |
cisplatin | ctrl | 5 669 | 12 034 | 42 944 | 41 288 | 9 536 |
pgp siRNA | 2 203** | 8 613** | 5 000*** | 32 663*** | 6 707** | |
bcrp siRNA | 3 300** | 8 540** | 17 699*** | 11 228*** | 8 177* | |
mrp1 siRNA | 1 339** | 10 090* | 20 348*** | 29 132*** | 5 695** | |
mrp3 siRNA | 303*** | 7 301** | 13 565*** | 11 163*** | 7 177* | |
cyclophosphamide | ctrl | 9 599 | 12 542 | 10 340 | 8 679 | 25 698 |
pgp siRNA | 8 432 | 11 755 | 10 242 | 7 912 | 15 443 | |
bcrp siRNA | 799*** | 2 086*** | 5705** | 2 463** | 765*** | |
mrp1 siRNA | 8 762 | 11 307 | 9 955 | 7 247 | 7 000 | |
mrp3 siRNA | 8 802 | 12 278 | 10 167 | 6 932 | 1 130 |